JP2004529925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529925A5 JP2004529925A5 JP2002581408A JP2002581408A JP2004529925A5 JP 2004529925 A5 JP2004529925 A5 JP 2004529925A5 JP 2002581408 A JP2002581408 A JP 2002581408A JP 2002581408 A JP2002581408 A JP 2002581408A JP 2004529925 A5 JP2004529925 A5 JP 2004529925A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- benzo
- phenyl
- diazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- -1 3-oxo-piperazin-1-yl Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- AZIZBYRGIGKTLW-UHFFFAOYSA-N 1,4-diazepin-2-one Chemical compound O=C1C=NC=CC=N1 AZIZBYRGIGKTLW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- QDKZHQGXPVFLHU-UHFFFAOYSA-N 1,5-benzodiazepin-2-one Chemical compound O=C1C=CN=C2C=CC=CC2=N1 QDKZHQGXPVFLHU-UHFFFAOYSA-N 0.000 claims 1
- GMNRSMAPXMAKAW-UHFFFAOYSA-N 1-(fluoromethyl)-3h-1,5-benzodiazepin-2-one Chemical compound N1=CCC(=O)N(CF)C2=CC=CC=C21 GMNRSMAPXMAKAW-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- JYOCYCDSXDFBGV-UHFFFAOYSA-N 1h-1,4-diazepine-7-carbonitrile Chemical compound N#CC1=CC=NC=CN1 JYOCYCDSXDFBGV-UHFFFAOYSA-N 0.000 claims 1
- CHYKGWNYCLLAKL-UHFFFAOYSA-N 3-(diazepin-1-yl)pyridine-2-carbonitrile Chemical compound N#CC1=NC=CC=C1N1N=CC=CC=C1 CHYKGWNYCLLAKL-UHFFFAOYSA-N 0.000 claims 1
- SLZWQLBLGIMSRX-UHFFFAOYSA-N 4-(3-imidazol-1-ylphenyl)-7-(2-methylpropylamino)-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(NCC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=C1 SLZWQLBLGIMSRX-UHFFFAOYSA-N 0.000 claims 1
- DJMZLSQXQSZBAN-UHFFFAOYSA-N 4-[2-oxo-7-(2,2,2-trifluoroethoxy)-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]pyridine-2-carbonitrile Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(OCC(F)(F)F)=CC=2N=C1C1=CC=NC(C#N)=C1 DJMZLSQXQSZBAN-UHFFFAOYSA-N 0.000 claims 1
- GBRPDPUYJNPHFW-UHFFFAOYSA-N 4-[2-oxo-7-pyrrolidin-1-yl-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]pyridine-2-carbonitrile Chemical compound FC(F)(F)C1=CC=2NC(=O)CC(C=3C=C(N=CC=3)C#N)=NC=2C=C1N1CCCC1 GBRPDPUYJNPHFW-UHFFFAOYSA-N 0.000 claims 1
- LGGCNWMQSRYKEK-UHFFFAOYSA-N 4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-7-[methyl(propan-2-yl)amino]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 LGGCNWMQSRYKEK-UHFFFAOYSA-N 0.000 claims 1
- OWPXWLMWINGIJA-UHFFFAOYSA-N 4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-7-[methyl(propyl)amino]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 OWPXWLMWINGIJA-UHFFFAOYSA-N 0.000 claims 1
- QVWATQZHVALIAI-UHFFFAOYSA-N 4-[3-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenyl]-7-[methyl(propyl)amino]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CS1 QVWATQZHVALIAI-UHFFFAOYSA-N 0.000 claims 1
- MOZPRFSXXYUWQA-UHFFFAOYSA-N 4-[3-[5-(azetidin-1-ylmethyl)triazol-1-yl]phenyl]-8-chloro-7-[methyl(2-methylpropyl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCC1 MOZPRFSXXYUWQA-UHFFFAOYSA-N 0.000 claims 1
- AKNWSIBZOBQZRO-UHFFFAOYSA-N 4-[3-[5-(azetidin-1-ylmethyl)triazol-1-yl]phenyl]-8-chloro-7-[methyl(propan-2-yl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCC1 AKNWSIBZOBQZRO-UHFFFAOYSA-N 0.000 claims 1
- QPHLWEQWHSMTNX-UHFFFAOYSA-N 4-[7-[cyclopropyl(methyl)amino]-2-oxo-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]pyridine-2-carbonitrile Chemical compound C=1C=2N=C(C=3C=C(N=CC=3)C#N)CC(=O)NC=2C=C(C(F)(F)F)C=1N(C)C1CC1 QPHLWEQWHSMTNX-UHFFFAOYSA-N 0.000 claims 1
- CZLWEHDNIPKFTN-UHFFFAOYSA-N 4-[7-[cyclopropylmethyl(methyl)amino]-2-oxo-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]pyridine-2-carbonitrile Chemical compound C=1C=2N=C(C=3C=C(N=CC=3)C#N)CC(=O)NC=2C=C(C(F)(F)F)C=1N(C)CC1CC1 CZLWEHDNIPKFTN-UHFFFAOYSA-N 0.000 claims 1
- VYNUPTPNOCSSBJ-UHFFFAOYSA-N 7-(diethylamino)-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-2-oxo-1,3-dihydro-1,5-benzodiazepine-8-carbonitrile Chemical compound C1C(=O)NC=2C=C(C#N)C(N(CC)CC)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 VYNUPTPNOCSSBJ-UHFFFAOYSA-N 0.000 claims 1
- DDDRVKGHRFVCSK-UHFFFAOYSA-N 7-(dimethylamino)-4-(3-imidazol-1-ylphenyl)-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=C1 DDDRVKGHRFVCSK-UHFFFAOYSA-N 0.000 claims 1
- UYLWLBKJGHXHEJ-UHFFFAOYSA-N 7-(dimethylamino)-4-[3-(2-methylpyrazol-3-yl)phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC=NN1C UYLWLBKJGHXHEJ-UHFFFAOYSA-N 0.000 claims 1
- ZZVIUNYEAUAGMT-UHFFFAOYSA-N 7-(dimethylamino)-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 ZZVIUNYEAUAGMT-UHFFFAOYSA-N 0.000 claims 1
- VAQIGIYSLWNPSM-UHFFFAOYSA-N 7-(dimethylamino)-4-[3-[4-(hydroxymethyl)-1,3-oxazol-2-yl]phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CO1 VAQIGIYSLWNPSM-UHFFFAOYSA-N 0.000 claims 1
- UXWOBRYNOZWNRK-UHFFFAOYSA-N 7-(dimethylamino)-4-[3-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CS1 UXWOBRYNOZWNRK-UHFFFAOYSA-N 0.000 claims 1
- AKHVLIYLESRYKL-UHFFFAOYSA-N 7-(dimethylamino)-8-(2-phenylethynyl)-4-[3-(triazol-1-yl)phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound CN(C)C1=CC=2N=C(C=3C=C(C=CC=3)N3N=NC=C3)CC(=O)NC=2C=C1C#CC1=CC=CC=C1 AKHVLIYLESRYKL-UHFFFAOYSA-N 0.000 claims 1
- OHWFEQKMVFNWLV-UHFFFAOYSA-N 7-(dimethylamino)-8-methyl-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C)C(N(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 OHWFEQKMVFNWLV-UHFFFAOYSA-N 0.000 claims 1
- HAAZRBAMJKYOAA-UHFFFAOYSA-N 7-[ethyl(methyl)amino]-8-methyl-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C)C(N(C)CC)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 HAAZRBAMJKYOAA-UHFFFAOYSA-N 0.000 claims 1
- NXJBMLLXZBHSHA-UHFFFAOYSA-N 7-[methyl(2-methylpropyl)amino]-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 NXJBMLLXZBHSHA-UHFFFAOYSA-N 0.000 claims 1
- GKGGRNXTYYJBPH-UHFFFAOYSA-N 7-[methyl(2-methylpropyl)amino]-4-[3-(triazol-1-yl)phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=N1 GKGGRNXTYYJBPH-UHFFFAOYSA-N 0.000 claims 1
- HWPJVWXJTPQBEF-UHFFFAOYSA-N 7-[methyl(2-methylpropyl)amino]-4-[3-[5-[[methyl(propan-2-yl)amino]methyl]triazol-1-yl]phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN(C)C(C)C HWPJVWXJTPQBEF-UHFFFAOYSA-N 0.000 claims 1
- GGCLCUPVAHZUHM-UHFFFAOYSA-N 7-[methyl(propan-2-yl)amino]-4-[3-[5-(pyrrolidin-1-ylmethyl)triazol-1-yl]phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCC1 GGCLCUPVAHZUHM-UHFFFAOYSA-N 0.000 claims 1
- JHMOJYCUDSVXIH-UHFFFAOYSA-N 7-[methyl(propyl)amino]-4-[3-(triazol-1-yl)phenyl]-8-(trifluoromethyl)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C(F)(F)F)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=N1 JHMOJYCUDSVXIH-UHFFFAOYSA-N 0.000 claims 1
- OGFPVPFGOGJHSX-UHFFFAOYSA-N 8-(2-fluorophenyl)-4-[3-(triazol-1-yl)phenyl]-7-(2,2,2-trifluoroethoxy)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound FC1=CC=CC=C1C(C(=C1)OCC(F)(F)F)=CC2=C1N=C(C=1C=C(C=CC=1)N1N=NC=C1)CC(=O)N2 OGFPVPFGOGJHSX-UHFFFAOYSA-N 0.000 claims 1
- PKAGRYFXAAQOOC-UHFFFAOYSA-N 8-chloro-4-(3-imidazol-1-ylphenyl)-7-(2-methylpropylamino)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(NCC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=C1 PKAGRYFXAAQOOC-UHFFFAOYSA-N 0.000 claims 1
- PFXSUPYIBPKVQN-UHFFFAOYSA-N 8-chloro-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-7-(2-methylpropylamino)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(NCC(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 PFXSUPYIBPKVQN-UHFFFAOYSA-N 0.000 claims 1
- BMMSJPYGKWFQKH-UHFFFAOYSA-N 8-chloro-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-7-(propan-2-ylamino)-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(NC(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 BMMSJPYGKWFQKH-UHFFFAOYSA-N 0.000 claims 1
- CWRWLBCLNIXFEP-UHFFFAOYSA-N 8-chloro-4-[3-[4-(hydroxymethyl)-1,3-oxazol-2-yl]phenyl]-7-[methyl(propan-2-yl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CO1 CWRWLBCLNIXFEP-UHFFFAOYSA-N 0.000 claims 1
- FNVVDXIMWWBIRY-UHFFFAOYSA-N 8-chloro-4-[3-[4-(hydroxymethyl)-1,3-oxazol-2-yl]phenyl]-7-[methyl(propyl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CO1 FNVVDXIMWWBIRY-UHFFFAOYSA-N 0.000 claims 1
- WHTNPSQCYHTFRC-UHFFFAOYSA-N 8-chloro-4-[3-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenyl]-7-[methyl(propan-2-yl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CS1 WHTNPSQCYHTFRC-UHFFFAOYSA-N 0.000 claims 1
- ADOSEGKIEQRXKL-UHFFFAOYSA-N 8-chloro-4-[3-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenyl]-7-[methyl(propyl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CS1 ADOSEGKIEQRXKL-UHFFFAOYSA-N 0.000 claims 1
- VGCFBGKWKFNEIC-UHFFFAOYSA-N 8-chloro-4-[3-[5-[(dimethylamino)methyl]triazol-1-yl]phenyl]-7-[methyl(2-methylpropyl)amino]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN(C)C VGCFBGKWKFNEIC-UHFFFAOYSA-N 0.000 claims 1
- JPOWMXAAAODWDG-UHFFFAOYSA-N 8-chloro-7-[ethyl(methyl)amino]-4-[3-[4-(hydroxymethyl)-1,3-oxazol-2-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CO1 JPOWMXAAAODWDG-UHFFFAOYSA-N 0.000 claims 1
- MDZRWNNRILAEHU-UHFFFAOYSA-N 8-chloro-7-[ethyl(methyl)amino]-4-[3-[4-(hydroxymethyl)-1,3-thiazol-2-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC)=CC=2N=C1C(C=1)=CC=CC=1C1=NC(CO)=CS1 MDZRWNNRILAEHU-UHFFFAOYSA-N 0.000 claims 1
- KMRCILAGDOXKQR-UHFFFAOYSA-N 8-chloro-7-[methyl(2-methylpropyl)amino]-4-[3-(triazol-1-yl)phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1C=CN=N1 KMRCILAGDOXKQR-UHFFFAOYSA-N 0.000 claims 1
- SOYNHYRIQYZWGC-UHFFFAOYSA-N 8-chloro-7-[methyl(2-methylpropyl)amino]-4-[3-[5-(piperidin-1-ylmethyl)triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCCC1 SOYNHYRIQYZWGC-UHFFFAOYSA-N 0.000 claims 1
- DHDNESILTRMMAB-UHFFFAOYSA-N 8-chloro-7-[methyl(2-methylpropyl)amino]-4-[3-[5-(pyrrolidin-1-ylmethyl)triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCC1 DHDNESILTRMMAB-UHFFFAOYSA-N 0.000 claims 1
- SAVDHCKDKXITDB-UHFFFAOYSA-N 8-chloro-7-[methyl(propan-2-yl)amino]-4-[3-[5-(pyrrolidin-1-ylmethyl)triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)C(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCC1 SAVDHCKDKXITDB-UHFFFAOYSA-N 0.000 claims 1
- VHBNDJVFQOPHQL-UHFFFAOYSA-N 8-chloro-7-[methyl(propan-2-yl)amino]-4-[3-[5-[[methyl(propan-2-yl)amino]methyl]triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound CC(C)N(C)CC1=CN=NN1C1=CC=CC(C=2CC(=O)NC3=CC(Cl)=C(N(C)C(C)C)C=C3N=2)=C1 VHBNDJVFQOPHQL-UHFFFAOYSA-N 0.000 claims 1
- YTKAPOCJJREWCQ-UHFFFAOYSA-N 8-chloro-7-[methyl(propyl)amino]-4-[3-[5-(pyrrolidin-1-ylmethyl)triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(Cl)C(N(C)CCC)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCC1 YTKAPOCJJREWCQ-UHFFFAOYSA-N 0.000 claims 1
- QBSNFNKYIAYAHP-UHFFFAOYSA-N 8-methyl-7-[methyl(2-methylpropyl)amino]-4-[3-(3-methyl-1,2-oxazol-5-yl)phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1C1=CC(C)=NO1 QBSNFNKYIAYAHP-UHFFFAOYSA-N 0.000 claims 1
- PUMGQYZLUWHXDO-UHFFFAOYSA-N 8-methyl-7-[methyl(2-methylpropyl)amino]-4-[3-[5-(pyrrolidin-1-ylmethyl)triazol-1-yl]phenyl]-1,3-dihydro-1,5-benzodiazepin-2-one Chemical compound C1C(=O)NC=2C=C(C)C(N(C)CC(C)C)=CC=2N=C1C(C=1)=CC=CC=1N1N=NC=C1CN1CCCC1 PUMGQYZLUWHXDO-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01109125 | 2001-04-12 | ||
| PCT/EP2002/003644 WO2002083652A1 (en) | 2001-04-12 | 2002-04-02 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004529925A JP2004529925A (ja) | 2004-09-30 |
| JP2004529925A5 true JP2004529925A5 (https=) | 2005-07-21 |
| JP4071115B2 JP4071115B2 (ja) | 2008-04-02 |
Family
ID=8177126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002581408A Expired - Fee Related JP4071115B2 (ja) | 2001-04-12 | 2002-04-02 | ｍＧｌｕＲ２アンタゴニストＩＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 |
Country Status (37)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE261945T1 (de) | 1999-10-15 | 2004-04-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| KR20090031962A (ko) * | 2001-12-27 | 2009-03-30 | 다이쇼 세이야꾸 가부시끼가이샤 | 6-플루오로비시클로[3.1.0]헥산 유도체 |
| DE60319812T2 (de) * | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| EP1925614A1 (en) * | 2002-03-28 | 2008-05-28 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| ES2293287T3 (es) * | 2003-07-25 | 2008-03-16 | F. Hoffmann-La Roche Ag | Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos. |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| BRPI0512330A (pt) * | 2004-06-21 | 2008-02-26 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| BRPI0607927A2 (pt) * | 2005-02-11 | 2009-10-20 | Hoffmann La Roche | derivados de pirazol-pirimidina |
| WO2006099972A1 (en) | 2005-03-23 | 2006-09-28 | F. Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
| CA2612419C (en) * | 2005-06-23 | 2017-06-13 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
| JP5048675B2 (ja) | 2005-09-27 | 2012-10-17 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類 |
| GB0600228D0 (en) * | 2006-01-06 | 2006-02-15 | Fermentas Uab | Inactivation method |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200808751A (en) * | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
| AU2007299129A1 (en) * | 2006-09-20 | 2008-03-27 | F. Hoffmann-La Roche Ag | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| ES2369866T3 (es) | 2007-04-19 | 2011-12-07 | F. Hoffmann-La Roche Ag | Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida. |
| CN101801930B (zh) * | 2007-09-14 | 2013-01-30 | 奥梅-杨森制药有限公司 | 1,3-二取代的-4-苯基-1h-吡啶-2-酮 |
| PL2200985T3 (pl) | 2007-09-14 | 2011-12-30 | Ortho Mcneil Janssen Pharmaceuticals Inc | 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5996532B2 (ja) | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| JP5790195B2 (ja) * | 2011-06-22 | 2015-10-07 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| CA2847247C (en) * | 2011-08-29 | 2019-10-15 | Sanford-Burnham Medical Research Institute | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| EP2877444B1 (en) | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| CN104736140A (zh) | 2012-10-23 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | 用于治疗自闭症的mGlu2/3拮抗剂 |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| MX386697B (es) | 2014-01-21 | 2025-03-19 | Janssen Pharmaceutica Nv | Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| JP2017513844A (ja) * | 2014-04-23 | 2017-06-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| CN108727345B (zh) * | 2017-04-25 | 2023-06-27 | 广东东阳光药业有限公司 | 一种咪唑环中间体的制备方法 |
| EP3737362B1 (en) | 2018-01-12 | 2025-10-15 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| CN108586447B (zh) * | 2018-01-19 | 2021-01-29 | 中国人民解放军第四军医大学 | 一种苯二氮杂卓化合物及其制备方法和应用 |
| TWI855088B (zh) * | 2019-06-06 | 2024-09-11 | 美商阿克思生物科學有限公司 | 製備胺基嘧啶化合物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU224435B1 (hu) * | 1995-02-09 | 2005-10-28 | EGIS Gyógyszergyár Rt. | Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények |
| SK283859B6 (sk) * | 1995-02-09 | 2004-03-02 | Egis Gy�Gyszergy�R Rt. | 1-[2'-(Substituovaný)vinyl]-5H-2,3-benzodiazepínové deriváty, spôsob ich prípravy a medziprodukty na ich prípravu, liečivá ich obsahujúce a ich použitie |
| MXPA02001340A (es) * | 1999-08-05 | 2004-07-16 | Prescient Neuropharma Inc | Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos. |
| BR0014859A (pt) * | 1999-10-15 | 2002-07-16 | Hoffmann La Roche | Derivados de benzodiazepina |
| ATE261945T1 (de) * | 1999-10-15 | 2004-04-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
-
2002
- 2002-04-02 CA CA002442557A patent/CA2442557C/en not_active Expired - Fee Related
- 2002-04-02 IL IL15787302A patent/IL157873A0/xx active IP Right Grant
- 2002-04-02 HU HU0400851A patent/HUP0400851A3/hu unknown
- 2002-04-02 KR KR1020037013300A patent/KR100566171B1/ko not_active Expired - Fee Related
- 2002-04-02 JP JP2002581408A patent/JP4071115B2/ja not_active Expired - Fee Related
- 2002-04-02 NZ NZ528315A patent/NZ528315A/en unknown
- 2002-04-02 RU RU2003130637/04A patent/RU2263112C2/ru not_active IP Right Cessation
- 2002-04-02 WO PCT/EP2002/003644 patent/WO2002083652A1/en not_active Ceased
- 2002-04-02 BR BR0208891-6A patent/BR0208891A/pt not_active Application Discontinuation
- 2002-04-02 EP EP02737911A patent/EP1379511B1/en not_active Expired - Lifetime
- 2002-04-02 PT PT02737911T patent/PT1379511E/pt unknown
- 2002-04-02 MX MXPA03009311A patent/MXPA03009311A/es active IP Right Grant
- 2002-04-02 ES ES02737911T patent/ES2246012T3/es not_active Expired - Lifetime
- 2002-04-02 CZ CZ20033003A patent/CZ20033003A3/cs unknown
- 2002-04-02 YU YU79003A patent/YU79003A/sh unknown
- 2002-04-02 DE DE60205100T patent/DE60205100T2/de not_active Expired - Lifetime
- 2002-04-02 DK DK02737911T patent/DK1379511T3/da active
- 2002-04-02 SI SI200230163T patent/SI1379511T1/xx unknown
- 2002-04-02 SK SK1368-2003A patent/SK13682003A3/sk unknown
- 2002-04-02 AT AT02737911T patent/ATE299868T1/de not_active IP Right Cessation
- 2002-04-02 AU AU2002312788A patent/AU2002312788B2/en not_active Ceased
- 2002-04-02 PL PL02367064A patent/PL367064A1/xx not_active Application Discontinuation
- 2002-04-02 HR HR20030792A patent/HRP20030792A2/hr not_active Application Discontinuation
- 2002-04-02 CN CNB028081811A patent/CN1264825C/zh not_active Expired - Fee Related
- 2002-04-03 US US10/115,826 patent/US6544985B2/en not_active Expired - Fee Related
- 2002-04-09 AR ARP020101290A patent/AR035816A1/es not_active Application Discontinuation
- 2002-04-09 PA PA20028543301A patent/PA8543301A1/es unknown
- 2002-04-10 PE PE2002000291A patent/PE20021041A1/es not_active Application Discontinuation
- 2002-04-10 JO JO200232A patent/JO2285B1/en active
- 2002-04-11 UY UY27258A patent/UY27258A1/es not_active Application Discontinuation
- 2002-04-11 MY MYPI20021345A patent/MY140271A/en unknown
- 2002-04-11 GT GT200200073A patent/GT200200073A/es unknown
-
2003
- 2003-09-11 IL IL157873A patent/IL157873A/en not_active IP Right Cessation
- 2003-09-16 ZA ZA200307243A patent/ZA200307243B/en unknown
- 2003-10-08 EC EC2003004797A patent/ECSP034797A/es unknown
- 2003-10-08 MA MA27346A patent/MA27012A1/fr unknown
- 2003-10-10 BG BG108254A patent/BG108254A/bg unknown
- 2003-10-10 NO NO20034576A patent/NO20034576L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529925A5 (https=) | ||
| RU2003130637A (ru) | Производные дигидробензо[b][1,4]диазепин-2-она в качестве антагонистов mglur2 11 | |
| JP2004525965A5 (https=) | ||
| IL158021A (en) | DIHYDRO - BENZO [b][1,4] DIAZEPIN - 2 - ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| KR100775720B1 (ko) | 도파민-ｄ3-수용체 친화성을 갖는 트리아졸 화합물 | |
| CN105407888B (zh) | 新双环溴结构域抑制剂 | |
| CA2474219A1 (en) | Dihydrobenzodiazepin-2-one derivatives iii | |
| US8242150B2 (en) | Triazole derivatives for treating alzheimer'S disease and related conditions | |
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| ES2307925T3 (es) | Antagonistas de los receptores de la taquiquinina. | |
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| CN109153649A (zh) | 烟碱乙酰胆碱受体的变构调节剂 | |
| CA2641379A1 (en) | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| JP2011526282A5 (https=) | ||
| US8987247B2 (en) | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders | |
| HRP20130957T1 (hr) | Derivati oksadiazola aktivni na sfingozin-1-fosfat (s1p) | |
| JP2007510689A5 (https=) | ||
| JP2007523182A5 (https=) | ||
| CA2386980A1 (en) | Benzodiazepine derivatives for use in acute or chronic neurological disorders | |
| CN102361867A (zh) | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 | |
| GB2292143A (en) | Pyrrolo-pyridine derivatives | |
| EA027351B1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| JP2010505809A5 (https=) | ||
| JP2020520354A5 (https=) |